|
SIMULTANEOUS TRANSLATION! SPECIAL RATES FOR DOMESTIC CHINA COMPANIES!
提供同声传译服务！特别为中国本土企业提供价格优惠！
Antibody-based therapeutics currently enjoys exceptional success in the global biologic drug market. Achieving a total sale of nearly US$35 billion and holding six spots out of the top 20 best-selling pharmaceutical products in 2008, monoclonal antibodies (mAb) sales are predicted to grow exponentially to reach US$50 billion in 2013.
Rising research interest is further compelled by the large market potential that these substances may offer. Its ability to treat a wide range of complex diseases relating to oncology, inflammation and autoimmune diseases make the development of novel, proprietary antibodies top on every biopharmaceutical companies’ list. In addition, biosimilar antibodies on its own also represent a huge, multibillion-dollar opportunity for generic manufactures in the United States, Europe and Asia.
With the latest hype in biosimilar antibodies and promising success in developing bi-specific antibodies using new platform, the advancement in the field of therapeutic antibodies unravel more commercial opportunities and renewed optimism for the industry, making it an even more lucrative and dynamic market for investors.
Join us at IBC’s 4 th Annual Antibody Asia conference to learn about the latest antibody research and development, industry trends and updates and ways to expedite your antibody pipeline into revenue-generating biologics. Held from 20 th to 22 nd February in Shanghai, we promise to put together the most beneficial and multi-faceted agenda, delivered by internationally renowned speakers, specially catered to match your interest.
Featuring presentations and case
studies from leading experts:
以下知名专家将会进行专题发言和案例分析： |
| ACADEMIA / 学术界 |
INDUSTRY /业界 |
 Prof Roy Jefferis, Professor Emeritus: Molecular Immunology,
School of Immunity & Infection, University of Birmingham, UK
|
 Dr Jijie Gu, Principal Research Scientist, Abbott Laboratories, USA |
 Prof Koichi Kato, Professor, Okazaki Institute for Integrative
Bioscience and Institute for Molecular Science, National Institutes
of Natural Sciences, Graduate School of Pharmaceutical
Sciences, Nagoya City University, Japan |
Prof Dr Dr Rolf G. Werner, Professorship of Industrial Biotechnology, University Tuebingen, Germany
|
 Prof Yajun Guo, Director, Chinese National Engineering
Research Centre for Antibody Medicine, China |
 Dr Ton Logtenberg, Chief Executive Officer, Merus, The Netherlands |
Plus
- Prof Yong-Sung Kim, Associate Professor, Dept. of Molecular Science
and Technology, Div. of Applied Chemistry & Biological Engineering, Ajou University, Korea
- Prof Dexian Zheng, Professor, National Laboratory of Medical Molecular
Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical
Sciences & Peking Union Medical College, Qinghua University, China
- Dr Larry Lo, Associate Director, Lead Development, Human Genome Sciences, USA
- Dr Shun Luo, President, JS Biosciences, China
- Dr Ralf Schumacher, Head of Biologics Research, Pharma Research and
Early Development, Roche Diagnostics, Germany
|
Event highlights: |
会议亮点 |
- Case studies from leading companies on revolutionizing
therapeutic antibodies R&D
- Perspectives and future of antibody R&D from Abbott, Boehringer
Ingelheim & Sandoz Biopharmaceuticals
- Innovation, trends and novel antibody development from Korea,
Japan, China and Singapore
- Global perspective and updates from USA, UK, Germany, Netherlands and more…
|
- 学习 世界知名公司进行以 革新型治疗性抗体的研发为主题的案例研究
- 倾听 雅培、勃林格殷格翰和 HSGI 公司 展望抗体研发的未来
- 获取有关韩国、日本、中国和新加坡各国 在创新研究、技术发展及新型抗体开发的第一手情况
- 倾听全球展望 并了解美国、英国、德国、荷兰及其他国家 / 地区的最新动向
|
Key themes and issues to be discussed include: |
- Examining the Business and Regulatory Landscape
- Cell Line and Antibodies Development for Biosimilars
- Novel Antibody Target Discovery
- Revolutionizing Therapeutic Antibody R&D
- Insights on Antibody Engineering Using New Technology Platforms
- The Future of Therapeutic Antibodies in Asia
|
|
Pre-Conference Workshop: 20 February 2012
A: Legal Strategies for the Commercialization
of Antibodies in Asia’s Evolving World of
Biopharmaceuticals and Biosimilars
Dr. Janet M. McNicholas, Partner, K&L Gates
Anne Dollard, General Counsel, Takeda San Francisco
Post Conference Workshop: 23 February 2012
B: Optimisation and Comparability of
Antibody Glycosylation
Prof Roy Jefferis, Professor Emeritus: Molecular Immunology,
Division of Immunity and Infection, University of Birmingham, UK
Dr Daryl Fernandes, Chief Executive, Ludger, Oxford, UK
Prof Koichi Kato, The Glycoscience Institute,
Ochanomizu University, Japanabc
|
|
|
|
|
Co-located |
|
|
